000282756 001__ 282756
000282756 005__ 20240229162359.0
000282756 0247_ $$2doi$$a10.1016/j.neo.2023.100934
000282756 0247_ $$2pmid$$apmid:37703626
000282756 0247_ $$2ISSN$$a1522-8002
000282756 0247_ $$2ISSN$$a1476-5586
000282756 0247_ $$2altmetric$$aaltmetric:154065092
000282756 037__ $$aDKFZ-2023-01875
000282756 041__ $$aEnglish
000282756 082__ $$a610
000282756 1001_ $$aHoffmann, Inga$$b0
000282756 245__ $$aIncreased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer.
000282756 260__ $$aBasingstoke$$bStockton Press$$c2023
000282756 3367_ $$2DRIVER$$aarticle
000282756 3367_ $$2DataCite$$aOutput Types/Journal article
000282756 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1694758399_28750
000282756 3367_ $$2BibTeX$$aARTICLE
000282756 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282756 3367_ $$00$$2EndNote$$aJournal Article
000282756 520__ $$aThe enzyme indoleamine 2,3-dioxygenase 1 (IDO1) plays a crucial role in regulating the immune system's response to tumors, but its exact role in cancer, especially in high-grade serous ovarian cancer (HGSOC), remains controversial. We aimed to investigate the prognostic impact of IDO1 expression and its correlation with tumor-infiltrating lymphocytes (TILs) in HGSOC.Immunohistochemical (IHC) staining and bioimage analysis using the QuPath software were employed to assess IDO1 protein expression in a well-characterized cohort of 507 patients with primary HGSOC. Statistical evaluation was performed using SPSS, and in silico validation considering IDO1 mRNA expression in bulk and single-cell gene expression datasets was conducted. Additionally, IDO1 expression in interferon-gamma (IFNG) stimulated HGSOC cell lines was analyzed.Our findings revealed that IDO1 protein and mRNA expression serve as positive prognostic markers for overall survival (OS) and progression-free survival (PFS) in HGSOC. High IDO1 expression was associated with a significant improvement in OS by 21 months (p < 0.001) and PFS by 6 months (p = 0.016). Notably, elevated IDO1 expression correlated with an increased number of CD3+ (p < 0.001), CD4+ (p < 0.001), and CD8+ TILs (p < 0.001). Furthermore, high IDO1 mRNA expression and protein level were found to be associated with enhanced responsiveness to pro-inflammatory cytokines, particularly IFNG.Our study provides evidence that IDO1 expression serves as a positive prognostic marker in HGSOC and is associated with an increased number of CD3+, CD4+ and CD8+ TILs. Understanding the intricate relationship between IDO1, TILs, and the tumor microenvironment may hold the key to improving outcomes in HGSOC.
000282756 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000282756 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000282756 650_7 $$2Other$$aHGSOC
000282756 650_7 $$2Other$$aIDO1
000282756 650_7 $$2Other$$aOvarian cancer
000282756 650_7 $$2Other$$aPrognostic marker
000282756 650_7 $$2Other$$aTILs
000282756 7001_ $$0P:(DE-He78)396821e874b632341e4bcabd27bcad3f$$aDragomir, Mihnea P$$b1$$udkfz
000282756 7001_ $$aMonjé, Nanna$$b2
000282756 7001_ $$aKeunecke, Carlotta$$b3
000282756 7001_ $$aKunze, Catarina Alisa$$b4
000282756 7001_ $$aSchallenberg, Simon$$b5
000282756 7001_ $$aMarchenko, Sofya$$b6
000282756 7001_ $$aSchmitt, Wolfgang D$$b7
000282756 7001_ $$aKulbe, Hagen$$b8
000282756 7001_ $$aSehouli, Jalid$$b9
000282756 7001_ $$aBraicu, Ioana Elena$$b10
000282756 7001_ $$aJank, Paul$$b11
000282756 7001_ $$aDenkert, Carsten$$b12
000282756 7001_ $$aDarb-Esfahani, Silvia$$b13
000282756 7001_ $$aHorst, David$$b14
000282756 7001_ $$aSinn, Bruno V$$b15
000282756 7001_ $$aSers, Christine$$b16
000282756 7001_ $$0P:(DE-He78)4cf7fbeff9b76780e2fd30c54400248b$$aBischoff, Philip$$b17$$udkfz
000282756 7001_ $$aTaube, Eliane T$$b18
000282756 773__ $$0PERI:(DE-600)2008231-9$$a10.1016/j.neo.2023.100934$$gVol. 44, p. 100934 -$$p100934$$tNeoplasia$$v44$$x1522-8002$$y2023
000282756 909CO $$ooai:inrepo02.dkfz.de:282756$$pVDB
000282756 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)396821e874b632341e4bcabd27bcad3f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000282756 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4cf7fbeff9b76780e2fd30c54400248b$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000282756 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000282756 9141_ $$y2023
000282756 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-16
000282756 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-16
000282756 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-16
000282756 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-16
000282756 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-16
000282756 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEOPLASIA : 2022$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T08:48:40Z
000282756 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T08:48:40Z
000282756 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T08:48:40Z
000282756 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000282756 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-22
000282756 9201_ $$0I:(DE-He78)BE01-20160331$$kBE01$$lDKTK Koordinierungsstelle Berlin$$x0
000282756 980__ $$ajournal
000282756 980__ $$aVDB
000282756 980__ $$aI:(DE-He78)BE01-20160331
000282756 980__ $$aUNRESTRICTED